Arcus Biosciences, Inc.

For the period ended Sep 30, 2025. Filed Oct 28, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 28, 2025

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In millions, except per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Revenues:
License and development services revenue (Includes $20, $23, $192 and $179 from a related party)	$20	$41	$192	$204
Other collaboration revenue (Includes $6, $7, $22 and $28 from a related party)	6	7	22	28
Total revenues	26	48	214	232
Operating expenses:
Research and development (Includes $13, ($2), $19 and ($32) from a related party)	141	123	402	347
General and administrative(Includes $3, $—, $5, and $— from a related party)	27	30	84	92
Impairment of long-lived assets (see Note 12, Leases)	—	—	—	20
Total operating expenses	168	153	486	459
Loss from operations	(142)	(105)	(272)	(227)
Non-operating income (expense):
Interest and other income, net	10	14	31	40
Interest expense	(3)	(1)	(6)	(2)
Total non-operating income, net	7	13	25	38
Loss before income taxes	(135)	(92)	(247)	(189)
Income tax expense	—	—	—	—
Net loss	$(135)	$(92)	$(247)	$(189)
Net loss per share:
Basic and diluted	$(1.27)	$(1.00)	$(2.39)	$(2.11)
Shares used to compute net loss per share:
Basic and diluted	106.5	91.4	103.7	89.6

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.